Category Specific RSS

biotech

Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24

A blue chip denotes the cream of the crop—the most put-together, high-quality company or share. So one can only imagine…

2 years ago

Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%

Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose…

2 years ago

Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials

Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis…

2 years ago

Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions

In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the…

2 years ago

Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled

Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly…

3 years ago

Pharmaxis cancer drug progress detailed at leading scientific conference, eyes FDA discussions in 2023

Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer,…

3 years ago